CNS Response, Inc. to Present at the BMO Capital Markets 8th Annual Healthcare Conference
July 30, 2008
CNS Response, Inc. to Present at the BMO Capital Markets 8th Annual Healthcare Conference
COSTA MESA, CA -- (MARKET WIRE) -- 07/30/08 -- CNS Response, Inc. (CNSO) announces that its Chairman and CEO, Leonard J. Brandt, and its President, George C. Carpenter, will present at the upcoming BMO Capital Markets 8th Annual Focus on Healthcare Conference. Mr. Brandt will briefly discuss the results of an independent study showing the successful use of Referenced-EEG to facilitate medication selection for hospitalized patients with severe eating disorders. The study was presented in May 2008 at the American Psychiatric Association.
The conference will be held August 5 and 6, 2008 at the Millennium Broadway Hotel in New York City. CNS Response management will present on Tuesday, August 5, at 4:00 p.m. Eastern (EDT). The presentation will be available as a live audio webcast at the following link:http://www.bmocm.com/conferences/2008healthcare/webcast/default.aspx. A replay of the webcast presentation will also be available at the CNS Response website, www.cnsresponse.com.
About CNS Response, Inc.
CNS Response is a life-sciences data company whose patented system provides treatment guidance to psychiatrists and other physicians for patients with behavioral (mental or addictive) disorders. This technology allows CNS Response to create and provide simple reports ("rEEG® Reports") that specifically guide physicians to treatment strategies based on the patient's own physiology.
rEEG® utilizes traditional electroencephalography (EEG) in conjunction with a normative database and a proprietary clinical (symptomatic) database to identify the following: (1) medication classes most likely to be needed; and (2) medications within these classes with the most probable treatment potential for each patient. Reports are provided to physicians in a relationship analogous to that of a reference laboratory. Prospective, retrospective and field studies of treatment-resistant patients have reported treatment success of 70% or greater in managed care, outpatient psychiatric and residential substance abuse clinical settings.
In addition to providing analytical support to physicians, CNS Response is also an aid to pharmaceutical developers, who can use rEEG to (1) stratify study populations to improve the success of FDA clinical trials; (2) provide insight on effective therapeutic dosing of investigational drugs; (3) identify additional indications for psychiatric medications; (4) provide insight into effective drug combinations; and (5) discover opportunities for decision analytics and support. In addition to these applications, CNS Response continues to investigate the use of rEEG analysis for development of proprietary pharmaceutical opportunities.
Investors and Media Contacts:
Marty Tullio
Managing Member
McCloud Communications, LLC
949.553.9748
Back to News and Press